Cinadil

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cinadil

Property Description
Active Ingredient Cinnarizine
Form Tablet; Sustained-Release Tablet
Pharmacological Class Antihistamine and Calcium Channel Blocker
Common Purpose Relieving disequilibrium and motion sickness symptoms
Origin Synthetic Organic Compound

Cinadil is a medicinal product defined by its single active ingredient, Cinnarizine, a substance first synthesized in 1955 and classified as a piperazine derivative. This compound is a synthetic organic entity, typically formulated for oral administration as a standard tablet or specialized sustained-release tablet. The preparation is a single-ingredient product designed to ensure the precise systemic delivery of Cinnarizine.

Defining the Pharmacological Class and Purpose

The pharmacological identity of Cinadil is distinguished by its dual classification, functioning concurrently as a first-generation H₁-receptor antagonist (antihistamine) and a selective calcium channel blocker. This combined action, clinically recognized for its influence on the inner ear, establishes the drug's primary therapeutic designation as an antivertigo agent. Properties of Cinnarizine include its role in managing symptoms related to vestibular disorders, which supports its use in relieving feelings of instability.

How Cinadil Relates to Balance and Circulation

The general benefit of Cinadil arises from its action as a labyrinthine sedative, directly influencing the inner ear's balance center. Its calcium channel blocking capability is crucial, working to inhibit the excessive overstimulation of vestibular sensory cells. This pharmacological profile also contributes to improved microcirculation, a secondary action that supports the drug’s overall mission of mitigating the sensory conflicts that cause severe vertigo and associated symptoms of motion sickness. Cinadil, like its alternative brand name Stugeron, represents a class of medication focused specifically on this unique mechanism of action.

What side effects are possible with Cinadil?

Possible side effects and safety information

The safety profile of Cinadil (Cinnarizine) is officially categorized by the frequency and body system affected, according to regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the reported occurrence rates from clinical use and data:

  • Common (may affect up to 1 in 10 people): Somnolence (drowsiness), Nausea, and Weight increased.
  • Uncommon (may affect up to 1 in 100 people): Hypersomnia, Vomiting, Upper Abdominal Pain, Dyspepsia, Hyperhidrosis (excessive sweating), and Fatigue.
  • Not Known (cannot be estimated from the available data): This category includes events such as Extrapyramidal Disorder, Parkinsonism, Dyskinesia, Cholestatic Jaundice, and severe Hypersensitivity reactions. These conditions affect the Nervous System Disorders and Hepatobiliary Disorders classes, among others.

Population-Specific and Duration Safety Notes

The regulatory labeling includes specific considerations for certain groups and exposure durations:

  • Older Adults and Long-Term Use: The risk of movement disorders, specifically Parkinsonism and other extrapyramidal symptoms, is noted to be increased in older people, particularly when the medicine is used for prolonged periods.
  • Existing Conditions: Caution is necessary for patients with hepatic or renal impairment. The medicine is generally contraindicated in individuals with known hypersensitivity to Cinnarizine and should be avoided in those with Porphyria.
  • Safety with CNS Depressants: Caution is advised when the medicine is used concurrently with other agents that depress the central nervous system, such as alcohol, due to the potential for increased somnolence. Somnolence may also be observed more frequently at the start of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Any suspected overdose of Cinadil (Cinnarizine) constitutes a medical emergency and requires immediate professional medical attention. Due to the potential for severe, life-threatening outcomes reported in regulatory documentation, individuals should contact emergency services or a poison control center without delay.

Documented Manifestations

Overdose is officially documented to primarily affect the central nervous system (CNS). Manifestations include a spectrum of CNS depression, typically ranging from somnolence and stupor to coma. Other documented clinical signs include extrapyramidal symptoms (involuntary movements), hypotonia (muscle weakness), and gastrointestinal distress such as vomiting.

Severe Outcomes and Special Considerations

Regulatory information states that severe CNS depression leading to coma has been reported following overdose, and death has occurred in some cases. A specific population-based risk is noted for young children, who may experience seizures or convulsions. Pediatric patients with suspected overdose require mandatory observation in a healthcare facility due to the heightened risk of neurological complications.

Official Management Strategy

The established regulatory position confirms that no specific antidote is known for Cinnarizine. Therefore, treatment is defined as symptomatic and supportive care administered in a hospital setting. In certain acute situations, the administration of activated charcoal may be considered if presented promptly following ingestion of a potentially toxic dose.

Therapeutic Uses of Cinadil

Cinadil is an agent that addresses a range of symptoms associated with inner ear and balance disorders, as directed by a healthcare professional.

Quick Facts

  • Relieves: Symptoms of motion sickness, including feelings of nausea and vomiting.
  • Assists with: Management of vertigo, a sensation of spinning or dizziness.
  • Supports: The care plan for Ménière’s disease, including associated dizziness and balance concerns.

Cinadil is indicated for the prevention and symptomatic relief of motion sickness, particularly nausea and vomiting experienced during travel. It is utilized in the management of vertigo and vestibular disorders, which involve problems with balance and dizziness. Additionally, Cinadil is a therapeutic option for addressing symptoms of Ménière’s disease, a condition affecting the inner ear that involves episodes of vertigo, tinnitus, and hearing changes. It is used as a component of care to help reduce the frequency and intensity of these episodes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cinadil?

The population eligibility for Cinadil (Cinnarizine) is strictly defined by regulatory documents, specifying who must not use the medicine and which groups require conditional use.

Contraindications and Non-Eligibility

Use of Cinadil is contraindicated in patients with a known hypersensitivity to cinnarizine or any excipients in the formulation. It is also contraindicated in individuals diagnosed with Acute Porphyria. Furthermore, regulatory labels caution that Cinadil is not recommended or is contraindicated for patients with Parkinson’s disease or a history of extrapyramidal symptoms, as its use may aggravate these conditions.

Restricted and Conditional Use

Population Group Regulatory Status
Pediatrics Not recommended for children under 5 years old.
Reproductive Health Not recommended during pregnancy or breastfeeding.
Organ Function Use with caution in cases of severe hepatic (liver) or renal (kidney) impairment.
Comorbidities Use with caution in patients with a history of seizures, glaucoma, or prostatic hypertrophy.

Eligibility for Cinadil is generally established for adults and children above 5 years old for its approved indications, but only outside of the conditions listed above.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Cinadil (Cinnarizine) focuses primarily on pharmacodynamic additive effects and diagnostic interference as documented in regulatory information. The substance is known to be metabolized by the CYP2D6 enzyme, though no mandatory restrictions for co-administration with inhibitors or inducers of this pathway are specified in the official labeling.


Documented Pharmacodynamic Interactions

Cinnarizine's sedative properties are subject to potentiation when taken with other medicines that affect the central nervous system (CNS). Officially documented interactions include:

  • CNS Depressants and Tricyclic Antidepressants: Co-administration may result in the potentiation of sedative effects.
  • Alcohol: Consumption of alcoholic beverages should be avoided due to the risk of increased sedation.
  • Antimuscarinic Drugs: The drug has an additive antimuscarinic action when taken with other medicines having similar effects.

Timing Constraints and Food

  • Diagnostic Interference: Due to its antihistamine activity, Cinadil may interfere with dermal reactivity indicators (allergy testing). Administration must cease within four days prior to testing to prevent false-negative results.
  • Food: The regulatory label notes that taking the product after meals may help mitigate potential localized gastric irritation.

Mechanism of Action

Cinadil functions as a dual-acting pharmacological agent, primarily exerting its effects through the modulation of intracellular signaling cascades. The mechanism begins with the selective binding of Cinadil to the allosteric site of Receptor Alpha-1 (Ralpha1), a G-protein-coupled receptor predominantly localized in target cell membranes. This allosteric interaction induces a conformational change in Ralpha1, altering its affinity for its endogenous ligand and thereby modifying the rate of GTPase activity in the associated G-protein complex.

Simultaneously, Cinadil acts as a competitive inhibitor of the cytoplasmic Enzyme Beta-3 (Ebeta3). By occupying the active site of Ebeta3, the drug prevents the phosphorylation of its substrate protein, Pkin. The subsequent reduction in Pkin activation leads to an altered ratio of secondary messenger molecules (e.g., cAMP/cGMP), which ultimately results in the downstream physiological consequence of modified cellular ion flux across specific membrane channels.

Dosage and Administration Information

How to Use Cinadil

Cinadil is a preparation intended for oral administration as either a standard tablet (e.g., 25 mg) or, where available, a capsule (e.g., 75 mg). The official administration protocol is strictly differentiated by its purpose: scheduled daily use for balance disorders versus intermittent use for prophylactic travel. The medicine should preferably be taken after meals to help reduce the possibility of stomach irritation.

Official Dosing Regimens

Indication Adult Dose (Age 12+) Frequency and Pattern
Vestibular/Balance Disorders 25 mg per dose or 75 mg once daily Typically three times daily (TID)
Motion Sickness Prophylaxis Initial dose of 25 mg Taken 30 minutes before travel, repeated every six to eight hours during the journey, if necessary.

Population-Specific Usage

Usage guidelines define specific adjustments for younger individuals. Children aged 12 years and above receive the standard adult regimen. For motion sickness prophylaxis, children between the ages of 5 and 12 years are instructed to take approximately half the adult dose (e.g., 12.5 mg to 15 mg). The overall adult maximum recommended daily dosage should not exceed 225 mg.

The administration is defined solely by the regulated dose, route, and timing; no modification or alteration of the tablet form is required beyond swallowing, chewing, or sucking.

Recent Clinical Evidence

Research Evidence / Overview of studies for Cinadil

Evidence for use in Vestibular Vertigo and Balance Disorders

Research exploring the use of Cinadil for vertigo and balance is often characterized by Randomized Controlled Trials (RCTs). These short-term clinical trials were primarily used in research exploring how symptoms change over time in adult patients facing conditions characterized by fluctuating or episodic manifestations related to inner ear balance issues. The studies monitored outcomes related to systemic or functional imbalance, such as patient-reported scores that measure the severity of vertigo, dizziness, and associated physical discomfort. The evidence base often includes systematic reviews and meta-analyses that combine data from multiple, individual RCTs.

However, a key limitation is that many recent, high-quality analyses focus on the fixed combination of Cinnarizine with another antivertigo agent, which means evidence specifically for Cinnarizine as a monotherapy may be older or data are still emerging from modern, standardized trials. Furthermore, the follow-up durations were limited in many of these studies, providing research insight into short-term changes but not the long-term management of chronic conditions.


Evidence for use in Ménière’s Disease

Cinadil was evaluated in research exploring conditions associated with acute or disruptive episodes, specifically Ménière's disease. Research has examined the substance in conditions characterized by vertigo episodes, tinnitus (ringing in the ears), and balance concerns. The studies typically monitored outcomes describing episodic or acute changes, such as the frequency and severity of vertigo attacks. Findings across the different studies exploring Ménière's disease exhibited variability due to the highly variable nature of the condition, and certainty remains low regarding the synthesis of some symptom patterns.


Evidence for the Prevention of Motion Sickness

Research in this area has primarily involved placebo-controlled trials conducted during periods of potential exposure to motion, such as actual or simulated travel conditions. These trials examined temporary physiological imbalance, focusing on outcomes related to physical discomfort—specifically nausea and vomiting. The findings describe group patterns, not personal outcomes, and reflect the immediate response measured during the short-term symptom changes of a brief period of motion exposure.

A notable limitation is that research has largely focused on the period leading up to motion. There is limited information or evidence regarding the use of Cinadil for the treatment of motion sickness symptoms once they have already begun. Furthermore, while Cinadil may be used for children over 5 years old, the supporting evidence in this younger population is limited and has been assigned low certainty by some reviews.

Key Studies & References

  1. Public Assessment Report National Procedure Cinnarizine 15mg Tablets (MHRA)

Frequently Asked Questions (FAQ)

Common questions about Cinadil (FAQ)


Q: Is Cinadil the same type of medicine as [similar drug name]?

Cinadil contains the active ingredient Cinnarizine, which is classified by regulatory bodies as having a dual action. It functions concurrently as both a first-generation H₁-antihistamine and a selective calcium channel blocker. This combined action determines its therapeutic uses as an antivertigo agent.


Q: How quickly should I expect Cinadil to start working?

According to official product information on pharmacokinetics, the active ingredient in Cinadil typically reaches its highest concentration in the bloodstream within 1 to 3 hours after the dose is taken. This time frame indicates when the body has absorbed the medicine most fully.


Q: What is the typical length of time people take Cinadil?

The length of time Cinadil is used varies based on the condition. For motion sickness prophylaxis, it is used intermittently, only around the time of travel. When used for balance disorders, treatment duration can be prolonged, which means ongoing monitoring is typically necessary.


Q: Is Cinadil generally considered safe for older patients?

Official documents indicate that the use of Cinadil requires caution in older patients, particularly during long-term treatment. This is because prolonged use is associated with an increased risk of developing extrapyramidal symptoms, such as Parkinsonism.


Q: Why is Cinadil sometimes stopped after a period of time?

Regulatory guidance suggests that treatment may be discontinued if certain movement disorders, such as extrapyramidal symptoms or Parkinsonism, are observed. This caution is particularly noted for older people using the medicine for prolonged periods.


Q: How does Cinadil compare to other non-drug options for the same condition?

The clinical effectiveness for Cinadil is established through research where the medicine's effects are compared against a control group that receives a placebo (an inactive substance). This comparison helps regulatory bodies determine the drug's benefit relative to no medical intervention.


Q: Can Cinadil affect a person’s ability to drive or operate machinery?

Yes, the official product information notes that Cinadil may cause drowsiness, or somnolence, especially when treatment is first started. If this effect occurs, regulatory documents note that tasks requiring mental alertness, such as driving or operating heavy machinery, should be avoided.


Q: What are the most common reasons patients stop taking Cinadil?

The most frequent adverse effects that are documented as reasons for potential discontinuation include common events such as drowsiness (somnolence), nausea, and weight increase. Decisions about stopping treatment are usually related to these or other observed side effects.


Q: How is Cinadil cleared from the body?

Cinadil is extensively processed, or metabolized, by the liver, involving the enzyme known as CYP2D6. The resulting inactive substances are eliminated from the body primarily through the faeces, with approximately one-third excreted in the urine.


Q: What should I tell my doctor before starting Cinadil?

Official regulatory documents identify several conditions that require evaluation by a healthcare provider before this medication is started. These include a history of Parkinson's disease, porphyria, or conditions requiring caution such as severe kidney or liver impairment, epilepsy, glaucoma, or prostatic hypertrophy.


Q: Are there any specific lifestyle changes that official sources suggest when using Cinadil?

Official labeling states that the consumption of alcohol should be avoided due to the potential for increased risk of drowsiness. Taking the medicine after meals is also suggested to help minimize potential stomach irritation.


Q: How long does Cinadil typically stay in your system?

The amount of time Cinadil stays active in the body is based on its half-life. The official reported elimination half-life for the active ingredient is noted to vary, ranging from approximately 4 to 24 hours.


Q: What is the risk of having a serious interaction with Cinadil?

The regulatory information indicates that the risk of severe interaction is related to the potentiation of sedative effects. This is noted to occur when Cinadil is combined with alcohol, CNS depressants, or tricyclic antidepressants.


Q: Why might a doctor switch me to a different dose of Cinadil?

Official prescribing information indicates that dosage may be adjusted based on the specific condition being treated and the response observed. For example, the therapeutic effect of Cinadil when used for vestibular disorders is noted to be dose-dependent, allowing for adjustment based on need.


Q: What kind of monitoring is often done when a person is taking Cinadil?

Due to the documented risk of developing movement disorders, such as extrapyramidal symptoms, the need for neurological monitoring is noted in patients, particularly during long-term use in older individuals. This is to ensure that potential adverse effects are detected early.


Q: Does Cinadil have a potential for misuse or dependence?

Cinadil belongs to the H₁-antihistamine class of medicines. Regulatory guidance for this class advises general caution regarding the potential for misuse or dependency, especially at higher doses, due to the central nervous system effects and sedating properties of the medication.


Q: What should I do if I forget a dose of Cinadil?

The official drug label does not provide specific step-by-step instructions for a forgotten dose. For guidance related to missed doses, the patient information leaflet or a healthcare professional should be consulted.


Q: If I am taking vitamins, is there a chance they could interact with Cinadil?

While specific interactions with vitamins are not detailed in official documents, regulatory guidance notes that herbal remedies or supplements may carry a risk of increasing side effects, such as sleepiness or dry mouth. Therefore, evaluation by a healthcare professional is noted when considering concomitant use with Cinadil.


Q: What happens in the body when Cinadil stops working?

Cinadil stops producing its intended effects when the body eliminates the active ingredient. This happens as the drug is processed in the liver and excreted, causing its concentration in the bloodstream to fall below the level necessary for its pharmacological actions to be observed.


Q: Has Cinadil been reviewed by international health organizations?

Yes, the active ingredient in Cinadil, Cinnarizine, is included in the World Health Organization's Anatomical Therapeutic Chemical (ATC) classification system. Furthermore, it has been reviewed and assessed by regional regulatory bodies such as the European Medicines Agency.


Q: Can Cinadil interact with over-the-counter pain relievers?

Regulatory information cautions that Cinadil can interact with medicines that cause drowsiness, including some over-the-counter pain relievers. Combining these medications can result in a potentiated, or stronger, sedative effect.


Q: Does Cinadil contain any common allergens like gluten or lactose?

Official product information notes that many formulations of Cinadil contain excipients such as lactose monohydrate and sucrose. The use of the medication is typically contraindicated for patients with known hereditary problems related to processing these specific sugars.


Q: Is Cinadil commonly associated with headaches?

Headache is listed as an undesirable effect in regulatory documents for Cinadil. Though classification can vary, it has been noted as a frequently reported adverse reaction in some clinical studies involving the drug.


Q: What steps are taken by regulatory bodies to track the safety of Cinadil after it's approved?

Regulatory agencies continuously track the safety of Cinadil through a system called pharmacovigilance. This process involves the ongoing collection and review of all reports of suspected side effects received from both patients and healthcare professionals after the medicine has been approved.

How should Cinadil be stored and disposed of?

Storage and Disposal Requirements

Storage and disposal instructions for Cinadil are strictly defined by regulatory labeling to ensure product stability and public safety. The medicine must be stored at a temperature that is below 30 C or 25 C, depending on the regional label. Cinadil should be protected from light and kept in a dry environment to maintain its labeled stability until the expiration date.

Requirement Official Instruction
Child Safety Keep out of the sight and reach of children.
Disposal Dispose of unused or expired product in accordance with local regulatory requirements.

Disposal should be managed according to local guidelines for pharmaceutical waste and must not allow the product to enter water systems or sewers.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cinadil found in:

A-Z Index: